Around September 26, 2026, Nature Communications published online a study by the team of Su Jinlong and Jiang Fulin at Hunan University in collaboration with the National University of Singapore and others: Using CALPHAD solidification simulation + machine learning surrogate models (hot cracking susceptibility/solidification interval/grain refinement factor) + NSGA-II multi-objective optimization, they designed a low-modulus biomedical β-titanium alloy Ti-15.8Nb-9.2Ta-10.0Zr-7.7Sn (ANTZS) specifically for LPBF. LPBF validation (400W/750mm/s): elastic modulus 42.7±2.1 GPa (far lower than Ti64's ~110 GPa, closer to human bone's 10-30 GPa), elongation 30.9±3.2%, cell compatibility (ISO 10993-5) superior to LPBF Ti64, targeting orthopedic implants and bone tissue engineering scaffolds. The "data-driven design-additive manufacturing validation" paradigm is proven, providing candidate grades for medical metal implants with mechanical properties closer to human bone. Value for powder buyers: if the new biomedical low-modulus β-titanium grade moves toward clinical mass production, it will translate into new composition demands for tantalum/niobium/zirconium-based titanium alloy powders; attention should be paid to customization opportunities for powder specifications (composition window/particle size) during the pilot scale-up phase of this grade.